Impact of body weight of IVF/ICSI patients on the pharmacokinetics and pharmacodynamic responses to FE 999049, a recombinant FSH derived from a human cell-line

被引：0
|
作者：
Klein, B. M. [1 ]
Arce, J. C. [2 ]
机构：
[1] Ferring Pharmaceut, Global Clin R&D Biometr, Copenhagen, Denmark
[2] Ferring Pharmaceut, Global Clin R&D Reprod Hlth, Copenhagen, Denmark
来源：
HUMAN REPRODUCTION | 2014年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-493
引用
收藏
页码：323 / 323
页数：1
相关论文
共 19 条
  • [1] A randomised, assessor-blind, dose-response trial in patients undergoing COS for IVF/ICSI with a novel recombinant FSH (FE 999049) derived from a human cell line
    Andersen, A. Nyboe
    Fernandez-Sanchez, M.
    Bosch, E.
    Visnova, H.
    Barri, P.
    Garcia-Velasco, J. A.
    De Sutter, P.
    Fauser, B. J. C. M.
    Arce, J. C.
    HUMAN REPRODUCTION, 2013, 28 : 351 - 352
  • [2] DOSE-RESPONSE ENDOCRINE PROFILES FOR A NOVEL RECOMBINANT FSH PREPARATION (FE 999049) DERIVED FROM A HUMAN CELL-LINE
    Andersen, A. Nyboe
    Barri, P.
    Garcia-Velasco, J. A.
    De Sutter, P.
    Bosch, E.
    Arce, J. -C.
    FERTILITY AND STERILITY, 2013, 100 (03) : S18 - S18
  • [3] The contribution of FSH receptor polymorphism on ovarian response and treatment efficiency following stimulation with FE 999049, a recombinant FSH from a human cell-line
    Arce, J. C.
    HUMAN REPRODUCTION, 2015, 30 : 438 - 438
  • [4] A RANDOMIZED, ASSESSOR-BLIND, DOSE-RESPONSE TRIAL IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION FOR IVF/ICSI WITH A NOVEL RECOMBINANT FSH PREPARATION (FE 999049) DERIVED FROM A HUMAN CELL-LINE.
    Arce, J. -C.
    Andersen, A. Nyboe
    Fernandez-Sanchez, M.
    Bosch, E.
    Visnova, H.
    Fauser, B. J. C. M.
    FERTILITY AND STERILITY, 2013, 100 (03) : S59 - S59
  • [5] Different pharmacokinetic properties between a novel recombinant FSH (FE 999049) derived from a human cell line and follitropin alfa
    Sandstrom, R.
    Olsson, H.
    Grundemar, L.
    HUMAN REPRODUCTION, 2013, 28 : 352 - 352
  • [6] Relation between dose of FE 999049, a recombinant FSH derived from a human cell-line, used for controlled ovarian stimulation and number of oocytes, embryos and blastocysts
    Arce, J. C.
    Nyboe Andersen, A.
    Fernandez-Sanchez, M.
    Visnova, H.
    Bosch, E.
    Garcia-Velasco, J. A.
    Barri, P.
    de Sutter, P.
    Klein, B. M.
    Fauser, B. C. J. M.
    HUMAN REPRODUCTION, 2014, 29 : 322 - 323
  • [7] The influence of patient-specific variables and dose-response modelling in controlled ovarian stimulation with FE 999049, a human recombinant FSH derived from a human cell-line
    Roshammar, D.
    Klein, B. M.
    Arce, J. C.
    HUMAN REPRODUCTION, 2014, 29 : 323 - 323
  • [8] Follicular and endocrine dose responses according to anti-Mullerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049)
    Bosch, Ernesto
    Andersen, Anders Nyboe
    Barri, Pedro
    Garcia-Velasco, Juan Antonio
    de Sutter, Petra
    Fernandez-Sanchez, Manuel
    Visnova, Hana
    Klein, Bjarke M.
    Mannaerts, Bernadette
    Arce, Joan-Carles
    CLINICAL ENDOCRINOLOGY, 2015, 83 (06) : 902 - 912
  • [9] A randomised, double-blind, active-controlled, multiple-dose trial investigating the pharmacokinetics and pharmacodynamics of a novel recombinant FSH (FE 999049) derived from a human cell line
    Olsson, H.
    Sandstrom, R.
    Grundemar, L.
    HUMAN REPRODUCTION, 2013, 28 : 351 - 351
  • [10] Follitropin delta - first human cell line derived recombinant FSH for AMH and body weight adjusted ovarian stimulation - a real world data analysis
    Bachmann, A.
    Kissler, S.
    Laubert, I.
    Mehrle, P.
    Mempel, A.
    Reissmann, C.
    Sauer, D.
    Tauchert, S.
    Bielfeld, A. P.
    HUMAN REPRODUCTION, 2020, 35 : 1453 - 1453
12